Jove
Visualize
Contáctanos
JoVE
x logofacebook logolinkedin logoyoutube logo
ACERCA DE JoVE
Visión GeneralLiderazgoBlogCentro de Ayuda JoVE
AUTORES
Proceso de PublicaciónConsejo EditorialAlcance y PolíticasRevisión por ParesPreguntas FrecuentesEnviar
BIBLIOTECARIOS
TestimoniosSuscripcionesAccesoRecursosConsejo Asesor de BibliotecasPreguntas Frecuentes
INVESTIGACIÓN
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchivo
EDUCACIÓN
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualCentro de Recursos para ProfesoresSitio de Profesores
Términos y Condiciones de Uso
Política de Privacidad
Políticas

Videos de Conceptos Relacionados

Neuromuscular Junction And Blockade01:29

Neuromuscular Junction And Blockade

5.1K
The site of chemical communication between a motor neuron and a muscle fiber is called the neuromuscular junction (NMJ). The end of the motor neuron at the NMJ divides into a cluster of synaptic end bulbs. The cytoplasm of these bulbs consists of synaptic vesicles enclosing acetylcholine molecules, the principal neurotransmitter released at the NMJ. The region opposite the synaptic bulb that ends in the muscle fiber is called the motor end plate, which has acetylcholine receptors. Within the...
5.1K
The Spindle Assembly Checkpoint02:19

The Spindle Assembly Checkpoint

3.9K
The spindle assembly checkpoint is a molecular surveillance mechanism ensuring the fidelity of chromosome segregation during anaphase. The checkpoint monitors the completion of all the prerequisite steps before chromosome segregation to determine whether the segregation process should proceed or be delayed.
Many proteins function together to control the spindle assembly checkpoint. Mutations affecting these proteins may allow cells to proceed into anaphase prematurely, resulting in the...
3.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.0K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.0K
Cancer02:18

Cancer

54.5K
Cancers arise due to mutations in genes involved in the regulation of cell division, which leads to unrestricted cell proliferation. Modern science and medicine have made great strides in the understanding and treatment of cancer, including eradicating cancer in some patients. However, there is still no cure for cancer. This is largely due to the fact that cancer is a large group of many diseases.
54.5K
What is Cancer?02:12

What is Cancer?

14.5K
Cells and tissues must meticulously coordinate their activities for the normal functioning of the human body. Therefore, they exhibit socially responsible behavior - resting, growing, dividing, differentiating, or dying - for the organism’s benefit. Cancer arises when cells divide uncontrollably and invade other tissues or organs.
Although people have known about cancer for centuries, it was only in 1761 that Giovanni Morgagni of Padua performed a detailed autopsy of...
14.5K
Cancer Vaccines01:30

Cancer Vaccines

1.1K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.1K

También podría leer

Artículos Relacionados

Artículos vinculados a este trabajo por autores compartidos, revista y gráfico de citas.

Ordenar por
Same author

Intravesical mesothelin-based CAR T cells targeting MUC16 effectively control bladder cancer in preclinical models.

The Journal of experimental medicine·2026
Same author

Addressing Biases in Analysis of Time of Infusion: NCI/SWOG Trial S1404 Among Participants With High-Risk Resectable Melanoma Who Received Adjuvant Anti-PD-1 Therapy.

JCO oncology practice·2026
Same author

Immune checkpoint blockade augments lymphodepleting chemotherapy-induced antitumor immunity by expanding effector CD8+ T cell clones.

Cancer research·2026
Same author

Reprogramming of TLR-Ferroptosis Signaling and Immunometabolic Pathways Overcomes Myeloid Suppression to Improve Checkpoint Blockade in Prostate Cancer.

Cancer research·2026
Same author

Whole-protein screening and multi-modal profiling of antigen-specific CD4<sup>+</sup> T cells at single-cell resolution.

Nature communications·2026
Same author

MONETTE: A Randomized Phase II Study of Ceralasertib plus Durvalumab or Ceralasertib Monotherapy in Patients with Advanced Melanoma Resistant to PD-(L)1 Inhibition.

Clinical cancer research : an official journal of the American Association for Cancer Research·2026

Video Experimental Relacionado

Updated: Feb 12, 2026

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K

Inmunoterapia contra el cáncer mediante el bloqueo de puntos de control

Antoni Ribas1, Jedd D Wolchok2,3

  • 1Department of Medicine, Division of Hematology-Oncology; Department of Surgery, Division of Surgical Oncology; and Department of Molecular and Medical Pharmacology, Jonsson Comprehensive Cancer Center and Parker Institute for Cancer Immunotherapy, University of California, Los Angeles, Los Angeles, CA 90095, USA. aribas@mednet.ucla.edu wolchokj@mskcc.org.

Science (New York, N.Y.)
|March 24, 2018
PubMed
Resumen
Este resumen es generado por máquina.

Los inhibidores del punto de control inmune como las terapias CTLA-4 y PD-1 ofrecen respuestas duraderas al cáncer. Sin embargo, puede surgir resistencia adquirida, potencialmente a través de la presentación de antígenos y alteraciones de la vía de interferón-γ, lo que requiere nuevas estrategias de combinación.

Más Videos Relacionados

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.0K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K

Videos de Experimentos Relacionados

Last Updated: Feb 12, 2026

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction
10:18

Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

Published on: July 7, 2023

1.7K
Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine
09:15

Experimental Melanoma Immunotherapy Model Using Tumor Vaccination with a Hematopoietic Cytokine

Published on: February 24, 2023

4.0K
Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy
06:51

Manufacturing Chimeric Antigen Receptor CAR T Cells for Adoptive Immunotherapy

Published on: December 17, 2019

16.0K

Área de la Ciencia:

  • Inmunología y Oncología
  • Inmunoterapia contra el cáncer

Sus antecedentes:

  • Los inhibidores del punto de control inmune dirigidos a la proteína 4 asociada a los linfocitos T citotóxicos (CTLA-4) y a las vías de muerte celular programada 1 (PD-1) han revolucionado el tratamiento del cáncer.
  • Estas terapias liberan células T antitumorales preexistentes, lo que lleva a respuestas duraderas en muchos pacientes de varios tipos de cáncer.

Objetivo del estudio:

  • Revisar la eficacia del bloqueo del punto de control inmunológico en el tratamiento del cáncer.
  • Explorar los mecanismos de la resistencia adquirida a estas terapias.
  • Discutir posibles nuevas estrategias combinatorias para superar la resistencia.

Principales métodos:

  • Revisión de los datos clínicos existentes y de la investigación preclínica sobre los inhibidores del punto de control inmunológico.
  • Análisis de los mecanismos propuestos que subyacen a la resistencia adquirida.
  • Evaluación de los nuevos enfoques de terapia combinada.

Principales resultados:

  • El bloqueo del punto de control inmune logra respuestas tumorales de larga duración sin precedentes en una población significativa de pacientes.
  • Aproximadamente un tercio de los pacientes eventualmente recae, lo que indica el desarrollo de resistencia adquirida.
  • La evidencia emergente sugiere que los mecanismos de resistencia implican alteraciones en la presentación de antígenos y la señalización de interferón-γ.

Conclusiones:

  • Si bien son efectivos, los inhibidores del punto de control inmunológico se enfrentan a desafíos con la resistencia adquirida.
  • Comprender las vías de resistencia es crucial para mejorar los resultados de los pacientes.
  • Las terapias combinatorias de próxima generación son prometedoras para superar estos mecanismos de resistencia y mejorar la inmunidad antitumoral.